MYOV - Myovant Sciences Has Limited Downside At Its Current Price
Myovant Sciences (MYOV) is a clinical-stage biopharma that is developing its lead candidate, relugolix, in multiple late-state indications. Like Urovant Sciences (UROV) that I have previously written about, Myovant is majority-owned by Sumitomo (DNPUF) which provides significant support to the company’s development efforts. As discussed in more detail below, I believe Myovant has a bright future and the potential to generate above-average returns for long-term shareholders.
Relugolix Could Have 3 Lucrative Indications Approved By The End Of 2021
Myovant’s main asset is relugolix. Relugolix is a direct antagonist of